Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells | Zendy

YA-CHUN LEE | Zendy; Liang-Ming Lee | Zendy; James ChihHsin Yang | Zendy; Anya Maan-Yuh Lin | Zendy; Yi-Chia Huang | Zendy; ChiaChi Hsu | Zendy; MENG-SHIAN CHEN | Zendy; ChinWen Chi | Zendy; Pen-Hui Yin | Zendy; ChengDeng Kuo | Zendy; JyhFei Liao | Zendy; HsinChen Lee | Zendy

Open Access

Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells

Author(s) -

YA-CHUN LEE,

Liang-Ming Lee,

James ChihHsin Yang,

Anya Maan-Yuh Lin,

Yi-Chia Huang,

ChiaChi Hsu,

MENG-SHIAN CHEN,

ChinWen Chi,

Pen-Hui Yin,

ChengDeng Kuo,

JyhFei Liao,

HsinChen Lee

Publication year - 2012

Publication title -

oncology reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.094

H-Index - 96

eISSN - 1791-2431

pISSN - 1021-335X

DOI - 10.3892/or.2012.2118

Subject(s) - gefitinib , cell cycle , cancer research , cisplatin , cell growth , epidermal growth factor receptor , cell , oncogene , apoptosis , cell cycle checkpoint , cancer cell , biology , cell culture , cancer , chemistry , biochemistry , chemotherapy , genetics

Norcantharidin is the demethylated analog of cantharidin isolated from blisterbeetles (Mylabris phalerata Pall.). In this study, we evaluated whether norcantharidinexhibits anticancer effects against the human non-small cell lung cancer celllines A549 (epidermal growth factor receptor (EGFR) mutation-negative) and PC9(EGFR mutation-positive). Our results revealed that norcantharidin dose-dependentlyretards cell growth, arrests cell cycle at G2/M phase, reduces cell migration,and even induces apoptosis at the concentration of 100 µM. Moreover, we foundthat norcantharidin enhances the anticancer effects of gefitinib and cisplatin.Norcantharidin exhibited similar potency of anticancer effects against the twocell lines with different EGFR mutation status and did not affect EGF-inducedEGFR phosphorylation, suggesting that the EGFR signaling may not be the targetof norcantharidin. In conclusion, our results suggest that norcantharidin exhibitsanticancer effects against non-small cell lung cancer cells in vitro and supportits potential as a chemotherapeutic agent for treating non-small cell lung cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research